YahooAugust 13, 2026 at 10:00 AM NY22 days ago

Can Keytruda Sustain Merck's Growth in the Second Half of 2026?

MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Companies in This Story